FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004363556> ?p ?o ?g. }

• W2004363556 endingPage "276" @default.
• W2004363556 startingPage "271" @default.
• W2004363556 abstract "Direct sequencing is the standard method for the detection of epidermal growth factor receptor (EGFR) mutations in lung cancer, however, its relatively low sensitivity limits its clinical use. Pyrosequencing is a bioluminometric, real-time non-electrophoretic DNA sequencing technique with a number of advantages compared with direct sequencing, including higher sensitivity, speed, automation and cost-effectiveness. Clinical specimens from 202 lung cancer patients were analyzed for EGFR mutations in exons 18, 19, 20 and 21 using the pyrosequencing method following genomic DNA extraction from paraffin-embedded tissue specimens. All clinical data and tumor specimens were obtained from the Konkuk University Hospital (Korea) between July 2006 and December 2008. The results and clinical responses to EGFR‑tyrosine kinase inhibitors (TKIs) were compared. Overall, EGFR mutation-positive rate was 26.7% (54/202). Activating EGFR mutations were observed more frequently in female (52.1 vs. 13.0%), non‑smoking (47.8 vs. 15.8%) and adenocarcinoma (35.2 vs. 5.2%) patients. However, significant numbers of EGFR mutation-positive patients were identified as male, former or current smokers and non-adenocarcinoma patients. The combinations of favorable clinicopathological factors, including female, non‑smoking and adenocarcinoma, were not identified to significantly increase the positive EGFR mutation rate (female, 52.1%; female and non-smoker, 52.6%; female, non-smoker and adenocarcinoma, 51.9%). The present findings indicate that EGFR mutation analysis is a highly useful method for the prediction of response to EGFR-TKI and the use of favorable clinicopathological factors to perform this analysis is not suitable. Exon 19 deletion was the most common mutation (63.6%) and exon 21 L858R substitution was measured at 32.7%. The exon 20 T790M mutation was identified in 1 patient prior to EGFR-TKI treatment. EGFR mutation status is associated with response to EGFR-TKI and the overall response rate in patients who have the activating EGFR mutation was 82.4 vs. 5.9% in patients with a wild‑type EGFR. The present study demonstrates that EGFR mutations analyzed by the pyrosequencing method are well correlated with clinicopathological parameters and that this method may be useful in the clinical practice." @default.
• W2004363556 created "2016-06-24" @default.
• W2004363556 creator A5006646503 @default.
• W2004363556 creator A5007822837 @default.
• W2004363556 creator A5011041611 @default.
• W2004363556 creator A5016889855 @default.
• W2004363556 creator A5026587236 @default.
• W2004363556 creator A5066767378 @default.
• W2004363556 creator A5084669649 @default.
• W2004363556 date "2012-10-01" @default.
• W2004363556 modified "2023-10-01" @default.
• W2004363556 title "Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients" @default.
• W2004363556 cites W1494567425 @default.
• W2004363556 cites W1589013348 @default.
• W2004363556 cites W1931438814 @default.
• W2004363556 cites W1969726210 @default.
• W2004363556 cites W1970433797 @default.
• W2004363556 cites W1988955103 @default.
• W2004363556 cites W1997860952 @default.
• W2004363556 cites W2006318114 @default.
• W2004363556 cites W2013733453 @default.
• W2004363556 cites W2014047578 @default.
• W2004363556 cites W2032490375 @default.
• W2004363556 cites W2044818287 @default.
• W2004363556 cites W2045060432 @default.
• W2004363556 cites W2049542146 @default.
• W2004363556 cites W2065752921 @default.
• W2004363556 cites W2066356996 @default.
• W2004363556 cites W2077858174 @default.
• W2004363556 cites W2083299269 @default.
• W2004363556 cites W2087058708 @default.
• W2004363556 cites W2096504879 @default.
• W2004363556 cites W2101329867 @default.
• W2004363556 cites W2111191667 @default.
• W2004363556 cites W2128165330 @default.
• W2004363556 cites W2129360604 @default.
• W2004363556 cites W2132157071 @default.
• W2004363556 cites W2143859186 @default.
• W2004363556 cites W2154729337 @default.
• W2004363556 cites W2166084034 @default.
• W2004363556 cites W3108750466 @default.
• W2004363556 doi "https://doi.org/10.3892/ol.2012.950" @default.
• W2004363556 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3525462" @default.
• W2004363556 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23255934" @default.
• W2004363556 hasPublicationYear "2012" @default.
• W2004363556 type Work @default.
• W2004363556 sameAs 2004363556 @default.
• W2004363556 citedByCount "31" @default.
• W2004363556 countsByYear W20043635562013 @default.
• W2004363556 countsByYear W20043635562014 @default.
• W2004363556 countsByYear W20043635562015 @default.
• W2004363556 countsByYear W20043635562016 @default.
• W2004363556 countsByYear W20043635562017 @default.
• W2004363556 countsByYear W20043635562018 @default.
• W2004363556 countsByYear W20043635562019 @default.
• W2004363556 countsByYear W20043635562020 @default.
• W2004363556 countsByYear W20043635562021 @default.
• W2004363556 countsByYear W20043635562022 @default.
• W2004363556 countsByYear W20043635562023 @default.
• W2004363556 crossrefType "journal-article" @default.
• W2004363556 hasAuthorship W2004363556A5006646503 @default.
• W2004363556 hasAuthorship W2004363556A5007822837 @default.
• W2004363556 hasAuthorship W2004363556A5011041611 @default.
• W2004363556 hasAuthorship W2004363556A5016889855 @default.
• W2004363556 hasAuthorship W2004363556A5026587236 @default.
• W2004363556 hasAuthorship W2004363556A5066767378 @default.
• W2004363556 hasAuthorship W2004363556A5084669649 @default.
• W2004363556 hasBestOaLocation W20043635561 @default.
• W2004363556 hasConcept C104317684 @default.
• W2004363556 hasConcept C121608353 @default.
• W2004363556 hasConcept C125009961 @default.
• W2004363556 hasConcept C126322002 @default.
• W2004363556 hasConcept C143998085 @default.
• W2004363556 hasConcept C2776256026 @default.
• W2004363556 hasConcept C2779438470 @default.
• W2004363556 hasConcept C2781018059 @default.
• W2004363556 hasConcept C2781182431 @default.
• W2004363556 hasConcept C29537977 @default.
• W2004363556 hasConcept C36823959 @default.
• W2004363556 hasConcept C501734568 @default.
• W2004363556 hasConcept C502942594 @default.
• W2004363556 hasConcept C54355233 @default.
• W2004363556 hasConcept C71924100 @default.
• W2004363556 hasConcept C86803240 @default.
• W2004363556 hasConcept C98638677 @default.
• W2004363556 hasConceptScore W2004363556C104317684 @default.
• W2004363556 hasConceptScore W2004363556C121608353 @default.
• W2004363556 hasConceptScore W2004363556C125009961 @default.
• W2004363556 hasConceptScore W2004363556C126322002 @default.
• W2004363556 hasConceptScore W2004363556C143998085 @default.
• W2004363556 hasConceptScore W2004363556C2776256026 @default.
• W2004363556 hasConceptScore W2004363556C2779438470 @default.
• W2004363556 hasConceptScore W2004363556C2781018059 @default.
• W2004363556 hasConceptScore W2004363556C2781182431 @default.
• W2004363556 hasConceptScore W2004363556C29537977 @default.
• W2004363556 hasConceptScore W2004363556C36823959 @default.
• W2004363556 hasConceptScore W2004363556C501734568 @default.
• W2004363556 hasConceptScore W2004363556C502942594 @default.

• next